The ABRC relies on subject matter experts (SMEs) from around the globe to evaluate the merits of grant applications received. Research Grant Peer Reviewers review each application in accordance with guidelines provided by ABRC and provide a written review and scores to ABRC.Continue reading→

The Arizona Legislature appropriated up to $5,000,000 beginning in fiscal year 2025-2026 to fund phase one (1), two (2), and/or three (3) clinical trials. This funding will run for five (5) years from the date of award and is exempt from lapsing.Continue reading→

Jennifer Barton, PhD, is spearheading an effort to diagnose ovarian cancer earlier and give high-risk patients a new option.Continue reading→

WASHINGTON, D.C. – AdvaMed, the Medtech Association, recently published a technical performance and safety bulletin titled, “Remote Device Operations: Common Challenges and Mitigation Strategies” to help health care providers, device manufacturers, and IT teams navigate the complex landscape of remotely managing medical devices.Continue reading→

The new systems represent a leap in non-invasive imaging. The machines, powered by artificial intelligence, open new possibilities for treating neurological diseases such as Alzheimer’s and Parkinson’s, as well as expanding the capabilities for imaging the heart, lungs and liver – even for patients with metallic implants.

Continue reading→

• Voluntary agreement meets the President’s four requests while also protecting the U.S. ecosystem responsible for America’s leadership in delivering medical breakthroughs
• Agreement provides certainty from tariffs and clarity on pricing framework that furthers Pfizer’s ability to expand investment in U.S.-based innovation and return manufacturing to the U.S.
• Pfizer to fully focus on delivering the next generation of cures, especially in cancer, obesity, vaccines, and inflammation and immunology
• Pfizer CEO Albert Bourla joins President Donald J. Trump and members of his Administration in White House event today

Continue reading→

TUCSON, Ariz., Sept. 30, 2025 — Critical Path Institute^® (C-Path) today announced the election of Colin Hill, M.S., to its Board of Directors. Hill brings deep experience at the intersection of artificial intelligence, drug development, and translational acceleration. The appointment will further strengthen C-Path’s Board of Directors’ commitment to provide optimal strategic support to the organization’s growth in advancing drug development through collaboration.Continue reading→

WASHINGTON, D.C. (September 29, 2025) – The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced three major actions as part of the biopharmaceutical industry’s commitment to American patients and workers. 

PhRMA member companies are making historic investments in U.S.-based manufacturing and infrastructure, providing financial assistance to millions of insured and underinsured patients who have been failed by a broken health insurance system, and announcing a new website that will simplify access to manufacturer direct purchase and patient assistance resources. Continue reading→

First X-ray machine’s commissioning milestone marks start of research phase for one-of-a-kind labContinue reading→

Managing Valley fever starts with awareness. Since there’s no surefire way to avoid getting Valley fever in Arizona, knowledge is everyone’s best defense — but awareness needs a community effort. Continue reading→